Clinical programme information
Provided independently by Stem Cells Center Malaysia
This page explains a provider-led clinical enquiry pathway involving mesenchymal stromal cells, specialised extracellular-vesicle or exosome preparations, and provider-described targeted precursor-cell approaches. Evidence for these interventions in autism remains preliminary. They are not established cures or replacements for developmental, behavioural, educational, medical or family support.
The clinical provider is responsible for assessment, product and laboratory verification, informed consent, treatment decisions, pricing, adverse-event planning and follow-up. My Autism Hub provides general information and enquiry routing only.
Programme overview
“Regenerative Therapy for Autism” is an umbrella description for a personalised clinical programme considered only after medical review. It should not be interpreted as a standard treatment recommendation.
Cell-based approach
Mesenchymal stromal cells, often shortened to MSCs, are being studied mainly for immunomodulatory and paracrine signalling effects. They should not be described as directly replacing neurons or reversing autism.
Cell-derived signalling
Exosomes are a type of extracellular vesicle carrying proteins, lipids and nucleic acids. Nebulised, inhaled or intranasal delivery remains experimental; product identity, dose, sterility, route and manufacturing controls are critical.
Provider-specific terminology
“Targeted stem cells” or precursor-cell preparations are not a single standardised therapy class. Families should request the exact cell type, source, processing method, intended biological rationale, regulatory status and quality-release criteria.
Current evidence
Clinical research is active, but autism studies vary widely in cell source, dose, route, participant characteristics, outcome measures and follow-up. Small or open-label studies cannot reliably prove benefit.
Research hypotheses include immune signalling, inflammation, oxidative stress, vascular support and paracrine communication. These are research rationales, not proof that a particular child has a treatable biological target.
Early-phase trials can help assess feasibility, short-term safety and whether a larger controlled study is justified. Exploratory changes in questionnaires or observations require cautious interpretation.
Larger randomised controlled trials, reproducible manufacturing standards, validated responder criteria, clinically meaningful endpoints and long-term safety monitoring are still needed.
Parent reports can be personally meaningful but cannot separate treatment effects from concurrent therapy, development, expectation, placebo effects, measurement variability or natural changes over time.
Assessment pathway
A responsible programme begins with records and clinical assessment—not a predetermined package. The treating team decides whether an enquiry should proceed, pause or be redirected.
Clarify the family’s concerns, current supports, expectations and reasons for considering this type of programme.
Review diagnosis, developmental profile, therapies, medications, allergies, seizures, infections, immune conditions, previous procedures and relevant specialist reports.
The provider may request laboratory testing, imaging or specialist opinions. Tests should answer a defined clinical question rather than serve as an automatic sales bundle.
Families should receive the cell or vesicle source, manufacturing information, route, planned dose, number of administrations, storage, release testing and chain-of-custody details.
Discuss uncertainty, risks, alternatives, concurrent therapies, follow-up, additional costs, refund terms and what happens if treatment is deferred or stopped.
Agree on realistic, observable goals and suitable standardised measures before treatment. Continue appropriate therapy and monitor both benefits and adverse effects.
Quality and traceability
Quality cannot be inferred from the words “stem cell,” “precursor cell” or “exosome.” Documentation should correspond to the exact product and batch being considered.
Potential risks
The following list is not exhaustive. The clinician must explain risks relevant to the individual, the product, the delivery route and any sedation or accompanying procedures.
Infusion, inhalation or administration reactions may include fever, chills, rash, breathing symptoms, blood-pressure changes, nausea or discomfort.
Poor donor screening, processing, storage or administration can introduce bacterial, viral, fungal, endotoxin or other contamination risks.
Allogeneic products may trigger immune responses. Cell infusions can also carry route-specific vascular or clotting concerns that require medical assessment.
Nebulised or inhaled preparations require attention to airway disease, formulation, particle delivery, sterility and emergency support.
Long-term safety, repeated dosing and interactions with other treatments may be uncertain, particularly for poorly characterised products.
Families should consider travel, accommodation, repeat dosing, investigations and the risk of diverting funds or time from established support.
Preparing for consultation
Bring this checklist to the consultation and ask for written answers where possible.
Ask for the source, cell or vesicle type, donor relationship, processing, passage or expansion details, dose or particle count, excipients and batch release criteria.
Request peer-reviewed human evidence that matches the product, route, dose and population—not evidence for a different cell product or condition.
Ask which authority, licence, ethics review, clinical-trial registration or institutional governance applies in the country where treatment is delivered.
Ask how the proposed programme compares with continuing existing therapy, addressing medical comorbidities, changing educational support or participating in a registered clinical trial.
Confirm baseline measures, follow-up dates, who records adverse events, how serious events are escalated and whether results are independently reviewed.
Request a written breakdown covering consultation, investigations, products, administration, medicines, travel, follow-up, repeat dosing and refund or cancellation terms.
Independent reading
These links help families evaluate regenerative interventions independently of a commercial consultation.
Patient guidance on approved treatments, clinical trials, risk, consent and warning signs.
Read the ISSCR guideReview registered studies and remember that registration does not itself prove approval, quality or efficacy.
Search registered studiesUS guidance on unapproved stem-cell and exosome products and the importance of regulatory review.
Read the consumer alertClinical decisions require direct assessment
Ask Stem Cells Center Malaysia for the exact protocol, product documentation, evidence, risks, alternatives, total cost and follow-up arrangements relevant to the individual.